Tag Archives: Donanemab

01Sep/23

New Alzheimer’s drugs don’t deserve the hype – here’s why

Sebastian Walsh, University of Cambridge

A prominent childhood memory is of my grandparents living with and then dying from dementia. As is universal with dementia, there was a double blow: watching my grandparents lose their identity and seeing the suffering of those closest to them.

Continue reading

18Jul/23

ALZHEIMER’S ASSOCIATION STATEMENT ON DONANEMAB PHASE 3 DATA REPORTED AT AAIC 2023

The data reported today by Eli Lilly from the TRAILBLAZER-ALZ 2 clinical trial of donanemab in early symptomatic Alzheimer’s disease demonstrate an important advancement in Alzheimer’s research and treatment. The full Phase 3 data was reported at the Alzheimer’s Association International Conference® (AAIC®) 2023, in Amsterdam, Netherlands, and online. The data were simultaneously published in the Journal of the American Medical Association. Continue reading